Waystar Reports Strong Q1 2026 Earnings Amid Stake Reduction
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 24 2026
0mins
Should l Buy WAY?
Source: Fool
Waystar Holding Corp's stock fell 14.56% as it crossed below the 5-day SMA, reflecting investor concerns despite positive earnings results.
The company reported $314 million in revenue for Q1 2026, a 22% year-over-year increase, and strong subscription revenue growth of 38%. However, Capricorn Fund Managers reduced its stake by 692,554 shares, valued at approximately $18.38 million, raising concerns about market confidence in Waystar's future growth potential. This reduction has led to a significant decline in Waystar's position within Capricorn's portfolio, now representing only 0.17% of their U.S. equity holdings.
Despite the stake reduction, Waystar's strong revenue growth and potential in the AI-driven healthcare market indicate a promising outlook. The company is expected to grow sales by 17% in 2026, suggesting that long-term investors may find value in its current valuation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WAY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WAY
Wall Street analysts forecast WAY stock price to rise
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 21.380
Low
40.00
Averages
47.81
High
54.00
Current: 21.380
Low
40.00
Averages
47.81
High
54.00
About WAY
Waystar Holding Corp. provides healthcare organizations with mission-critical cloud software that simplifies healthcare payments. The Company’s enterprise-grade platform, Waystar, streamlines the complex processes. It leverages internally developed artificial intelligence (AI) as well as proprietary, advanced algorithms to automate payment-related workflow tasks and drive continuous improvement, which enhances claim and billing accuracy, enriches data integrity, and reduces labor costs for providers. Its software is used daily by providers of all types and sizes across the continuum of care, including physician practices, clinics, surgical centers, and laboratories, as well as large hospitals and health systems. The Company’s clients utilize its software to manage pre-encounter workflows, such as eligibility checks and prior authorization approvals, as well as mid- and post-encounter workflows, such as co-pay collection, claims submission and monitoring, and payer remittances.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Waystar Q1 2026 Earnings Call Insights
- Significant Revenue Growth: Waystar achieved $314 million in revenue for Q1 2026, reflecting a 22% year-over-year increase, demonstrating strong execution in its healthcare revenue cycle platform and reinforcing its market leadership.
- AI-Driven Market Opportunity: The CEO indicated that the application of AI technology expands Waystar's addressable market from a $20 billion software market to a $100 billion annual revenue cycle labor services market, signaling substantial future growth potential.
- Strong Subscription Revenue: Subscription revenue reached $172 million in Q1, up 38% year-over-year, indicating significant progress in attracting customers and enhancing service quality, which strengthens the company's long-term profitability.
- Adjusted EBITDA Growth: The adjusted EBITDA for Q1 was $135 million, a 26% year-over-year increase, with an EBITDA margin of 43%, primarily driven by a shift to higher-margin solutions, showcasing the company's success in optimizing its cost structure.
See More
Waystar (WAY) Q1 2026 Earnings Call Transcript
See More
Capricorn Fund Managers Reduces Waystar Stake by 692,554 Shares
- Stake Reduction Details: According to an SEC filing dated April 24, 2026, Capricorn Fund Managers reduced its stake in Waystar by 692,554 shares during Q1 2026, with an estimated transaction value of $18.38 million, resulting in a quarter-end position value decline of $23.08 million due to both the sale and market price changes.
- Holding Proportion Shift: Following the sale, Waystar now represents only 0.17% of Capricorn's $641.43 million U.S. equity holdings, indicating a marginalization of Waystar within its investment portfolio.
- Market Performance Analysis: As of April 23, 2026, Waystar shares traded at $24.85, reflecting a 32.5% decline over the past year and underperforming the S&P 500 by 65 percentage points, highlighting market concerns regarding its future growth prospects.
- Investor Outlook: While Capricorn's stake reduction may raise market concerns, Waystar is projected to grow sales by 17% in 2026 and is leveraging AI technology to enhance its solutions, indicating potential in the healthcare payments sector and a reasonable valuation that may attract long-term investors.
See More
Capricorn Reduces Stake in Waystar by 692,554 Shares
- Share Reduction Scale: Capricorn reduced its stake in Waystar by 692,554 shares in Q1 2026, with an estimated transaction value of $18.38 million, reflecting its strategic response to market volatility.
- Decline in Position Value: This transaction resulted in a $23.08 million drop in the quarter-end value of Capricorn's Waystar holdings, indicating the direct impact of market price changes on its asset management.
- Change in Holdings Proportion: Following the sale, Waystar now represents only 0.17% of Capricorn's AUM, no longer qualifying as one of its top five holdings, which signifies a significant reduction in its importance within the investment portfolio.
- Market Performance Analysis: Waystar's stock price has decreased by 32.5% over the past year and underperformed the S&P 500 by 65 percentage points, highlighting the competitive pressures and lack of investor confidence in the market.
See More
Waystar Unveils New AI-Driven Capabilities
- AI Capability Enhancement: Waystar's newly launched AltitudeAI™ capabilities aim to achieve double-digit reductions in providers' manual workflows, unlocking billions in previously hidden revenue losses, thereby significantly enhancing healthcare payment efficiency and revenue recovery capabilities.
- Massive Transaction Scale: Waystar's AI-powered payment ecosystem processes over 7.5 billion transactions annually, covering one in three U.S. hospital discharges, which provides a robust foundation for its models to learn from outcomes and enables providers to focus on higher-value work.
- Partnership Expansion: Waystar's collaboration with Google Cloud continues to deepen, with the adoption of AltitudeAI growing steadily, successfully preventing $15.5 billion in denials and reducing denial appeal and recovery time by 90%, thus improving clients' financial performance.
- Innovation Showcase Event: Waystar will unveil its latest product innovations at the Spring 2026 Innovation Showcase, emphasizing its leadership in the healthcare payments sector and driving the realization of a fully autonomous revenue cycle platform through ongoing technological advancements.
See More
Waystar Unveils AI-Driven Innovations for Revenue Cycle Management
- Revenue Cycle Automation: Waystar's new AltitudeAI™ capabilities aim to achieve double-digit reductions in providers' manual workflows while uncovering billions in potential revenue loss, significantly enhancing efficiency and accuracy in healthcare payments.
- Denial Management Optimization: The new system automatically matches recoupments to the correct claims, enabling providers to identify unjustified take-backs, with early adopter health systems expected to match $32 million in revenue risk and reduce reconciliation time by 80%.
- Revenue Recovery Enhancement: By converging financial and clinical intelligence, Waystar enables an estimated $3 million in net revenue per 10,000 patient discharges, with a projected 5x return in recovered revenue over three years, greatly improving financial performance.
- Personalized Patient Experience: The newly introduced self-service payment experience dynamically generates personalized payment and discount offers in real time, with an expected increase of up to 50% in collections, accelerating AR days and reducing bad debt write-offs.
See More
Waystar Q1 2026 Earnings Call Insights
- Significant Revenue Growth: Waystar achieved $314 million in revenue for Q1 2026, reflecting a 22% year-over-year increase, demonstrating strong execution in its healthcare revenue cycle platform and reinforcing its market leadership.
- AI-Driven Market Opportunity: The CEO indicated that the application of AI technology expands Waystar's addressable market from a $20 billion software market to a $100 billion annual revenue cycle labor services market, signaling substantial future growth potential.
- Strong Subscription Revenue: Subscription revenue reached $172 million in Q1, up 38% year-over-year, indicating significant progress in attracting customers and enhancing service quality, which strengthens the company's long-term profitability.
- Adjusted EBITDA Growth: The adjusted EBITDA for Q1 was $135 million, a 26% year-over-year increase, with an EBITDA margin of 43%, primarily driven by a shift to higher-margin solutions, showcasing the company's success in optimizing its cost structure.
See More
Waystar (WAY) Q1 2026 Earnings Call Transcript
See More
Capricorn Fund Managers Reduces Waystar Stake by 692,554 Shares
- Stake Reduction Details: According to an SEC filing dated April 24, 2026, Capricorn Fund Managers reduced its stake in Waystar by 692,554 shares during Q1 2026, with an estimated transaction value of $18.38 million, resulting in a quarter-end position value decline of $23.08 million due to both the sale and market price changes.
- Holding Proportion Shift: Following the sale, Waystar now represents only 0.17% of Capricorn's $641.43 million U.S. equity holdings, indicating a marginalization of Waystar within its investment portfolio.
- Market Performance Analysis: As of April 23, 2026, Waystar shares traded at $24.85, reflecting a 32.5% decline over the past year and underperforming the S&P 500 by 65 percentage points, highlighting market concerns regarding its future growth prospects.
- Investor Outlook: While Capricorn's stake reduction may raise market concerns, Waystar is projected to grow sales by 17% in 2026 and is leveraging AI technology to enhance its solutions, indicating potential in the healthcare payments sector and a reasonable valuation that may attract long-term investors.
See More
Capricorn Reduces Stake in Waystar by 692,554 Shares
- Share Reduction Scale: Capricorn reduced its stake in Waystar by 692,554 shares in Q1 2026, with an estimated transaction value of $18.38 million, reflecting its strategic response to market volatility.
- Decline in Position Value: This transaction resulted in a $23.08 million drop in the quarter-end value of Capricorn's Waystar holdings, indicating the direct impact of market price changes on its asset management.
- Change in Holdings Proportion: Following the sale, Waystar now represents only 0.17% of Capricorn's AUM, no longer qualifying as one of its top five holdings, which signifies a significant reduction in its importance within the investment portfolio.
- Market Performance Analysis: Waystar's stock price has decreased by 32.5% over the past year and underperformed the S&P 500 by 65 percentage points, highlighting the competitive pressures and lack of investor confidence in the market.
See More
Waystar Unveils New AI-Driven Capabilities
- AI Capability Enhancement: Waystar's newly launched AltitudeAI™ capabilities aim to achieve double-digit reductions in providers' manual workflows, unlocking billions in previously hidden revenue losses, thereby significantly enhancing healthcare payment efficiency and revenue recovery capabilities.
- Massive Transaction Scale: Waystar's AI-powered payment ecosystem processes over 7.5 billion transactions annually, covering one in three U.S. hospital discharges, which provides a robust foundation for its models to learn from outcomes and enables providers to focus on higher-value work.
- Partnership Expansion: Waystar's collaboration with Google Cloud continues to deepen, with the adoption of AltitudeAI growing steadily, successfully preventing $15.5 billion in denials and reducing denial appeal and recovery time by 90%, thus improving clients' financial performance.
- Innovation Showcase Event: Waystar will unveil its latest product innovations at the Spring 2026 Innovation Showcase, emphasizing its leadership in the healthcare payments sector and driving the realization of a fully autonomous revenue cycle platform through ongoing technological advancements.
See More
Waystar Unveils AI-Driven Innovations for Revenue Cycle Management
- Revenue Cycle Automation: Waystar's new AltitudeAI™ capabilities aim to achieve double-digit reductions in providers' manual workflows while uncovering billions in potential revenue loss, significantly enhancing efficiency and accuracy in healthcare payments.
- Denial Management Optimization: The new system automatically matches recoupments to the correct claims, enabling providers to identify unjustified take-backs, with early adopter health systems expected to match $32 million in revenue risk and reduce reconciliation time by 80%.
- Revenue Recovery Enhancement: By converging financial and clinical intelligence, Waystar enables an estimated $3 million in net revenue per 10,000 patient discharges, with a projected 5x return in recovered revenue over three years, greatly improving financial performance.
- Personalized Patient Experience: The newly introduced self-service payment experience dynamically generates personalized payment and discount offers in real time, with an expected increase of up to 50% in collections, accelerating AR days and reducing bad debt write-offs.
See More
